GlaxoSmithKline (NYSE:GSK) announces positive results from a Phase 2 clinical trial, DREAMM-2, evaluating antibody-drug conjugate (ADC) belantamab mafodotin (GSK2857916) in patients with relapsed multiple myeloma who failed to respond to an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody.
The study met the primary objective of overall response rate.
No new safety signals were observed.
The data will be submitted for presentation at a future medical conference.
The results will support regulatory filings later this year.
An earlier study, DREAMM-1, was also successful.
Belantamab mafodotin consists of a humanized anti-BCMA monoclonal antibody linked to a cytotoxic drug called monomethyl auristatin-F. GSK in-licensed the linker technology from Seattle Genetics (NASDAQ:SGEN).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.